| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OXACILLIN SODIUM | 206681 | 002 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 2GM BASE/VIAL | No | No | 2017/09/11 | 2017/09/11 | PIRAMAL CRITICAL | Discontinued |
| OXACILLIN SODIUM | 206760 | 001 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 10GM BASE/VIAL | No | No | 2017/10/26 | 2017/10/26 | PIRAMAL CRITICAL | Discontinued |
| OXACILLIN SODIUM | 207148 | 001 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 10GM BASE/VIAL | No | No | 2017/11/24 | 2017/11/24 | WOCKHARDT BIO AG | Prescription |
| OXACILLIN SODIUM | 206198 | 001 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 1GM BASE/VIAL | No | Yes | 2020/07/20 | 2020/07/20 | FRESENIUS KABI USA | Prescription |
| OXACILLIN SODIUM | 206198 | 002 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 2GM BASE/VIAL | No | Yes | 2020/07/20 | 2020/07/20 | FRESENIUS KABI USA | Prescription |
| OXACILLIN SODIUM | 206199 | 001 | ANDA | OXACILLIN SODIUM | INJECTABLE;INJECTION | EQ 10GM BASE/VIAL | No | No | 2020/07/27 | 2020/07/27 | FRESENIUS KABI USA | Prescription |
| DICLOXACILLIN SODIUM | 216845 | 001 | ANDA | DICLOXACILLIN SODIUM | CAPSULE;ORAL | EQ 250MG BASE | No | No | 2022/09/23 | 2022/09/23 | AUROBINDO PHARMA | Prescription |
| DICLOXACILLIN SODIUM | 216845 | 002 | ANDA | DICLOXACILLIN SODIUM | CAPSULE;ORAL | EQ 500MG BASE | No | No | 2022/09/23 | 2022/09/23 | AUROBINDO PHARMA | Prescription |